417 related articles for article (PubMed ID: 16475973)
1. Rho GTPases: promising cellular targets for novel anticancer drugs.
Fritz G; Kaina B
Curr Cancer Drug Targets; 2006 Feb; 6(1):1-14. PubMed ID: 16475973
[TBL] [Abstract][Full Text] [Related]
2. HMG-CoA reductase inhibitors (statins) as anticancer drugs (review).
Fritz G
Int J Oncol; 2005 Nov; 27(5):1401-9. PubMed ID: 16211237
[TBL] [Abstract][Full Text] [Related]
3. Rho GDP dissociation inhibitors as potential targets for anticancer treatment.
Zhang B
Drug Resist Updat; 2006 Jun; 9(3):134-41. PubMed ID: 16807067
[TBL] [Abstract][Full Text] [Related]
4. Rho GTPases and regulation of hematopoietic stem cell localization.
Williams DA; Zheng Y; Cancelas JA
Methods Enzymol; 2008; 439():365-93. PubMed ID: 18374178
[TBL] [Abstract][Full Text] [Related]
5. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer.
Graaf MR; Richel DJ; van Noorden CJ; Guchelaar HJ
Cancer Treat Rev; 2004 Nov; 30(7):609-41. PubMed ID: 15531395
[TBL] [Abstract][Full Text] [Related]
6. Biochemical analyses of the Wrch atypical Rho family GTPases.
Shutes A; Berzat AC; Chenette EJ; Cox AD; Der CJ
Methods Enzymol; 2006; 406():11-26. PubMed ID: 16472646
[TBL] [Abstract][Full Text] [Related]
7. Rho GTPases: potential candidates for anticancer therapy.
Aznar S; Fernández-Valerón P; Espina C; Lacal JC
Cancer Lett; 2004 Apr; 206(2):181-91. PubMed ID: 15013523
[TBL] [Abstract][Full Text] [Related]
8. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
DuHadaway JB; Du W; Donover S; Baker J; Liu AX; Sharp DM; Muller AJ; Prendergast GC
Oncogene; 2003 Jun; 22(23):3578-88. PubMed ID: 12789266
[TBL] [Abstract][Full Text] [Related]
9. Targeting Ras and Rho GTPases as opportunities for cancer therapeutics.
Walker K; Olson MF
Curr Opin Genet Dev; 2005 Feb; 15(1):62-8. PubMed ID: 15661535
[TBL] [Abstract][Full Text] [Related]
10. Using inhibitors of prenylation to block localization and transforming activity.
Berzat AC; Brady DC; Fiordalisi JJ; Cox AD
Methods Enzymol; 2006; 407():575-97. PubMed ID: 16757354
[TBL] [Abstract][Full Text] [Related]
11. Rho family proteins and Ras transformation: the RHOad less traveled gets congested.
Zohn IM; Campbell SL; Khosravi-Far R; Rossman KL; Der CJ
Oncogene; 1998 Sep; 17(11 Reviews):1415-38. PubMed ID: 9779988
[TBL] [Abstract][Full Text] [Related]
12. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.
Lebowitz PF; Prendergast GC
Oncogene; 1998 Sep; 17(11 Reviews):1439-45. PubMed ID: 9779989
[TBL] [Abstract][Full Text] [Related]
13. PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility.
Fiordalisi JJ; Keller PJ; Cox AD
Cancer Res; 2006 Mar; 66(6):3153-61. PubMed ID: 16540666
[TBL] [Abstract][Full Text] [Related]
14. Potential antitumor effects of statins (Review).
Jakobisiak M; Golab J
Int J Oncol; 2003 Oct; 23(4):1055-69. PubMed ID: 12963986
[TBL] [Abstract][Full Text] [Related]
15. Taking Rho GTPases to the next level: the cellular functions of atypical Rho GTPases.
Aspenström P; Ruusala A; Pacholsky D
Exp Cell Res; 2007 Oct; 313(17):3673-9. PubMed ID: 17850788
[TBL] [Abstract][Full Text] [Related]
16. Maspin controls mammary tumor cell migration through inhibiting Rac1 and Cdc42, but not the RhoA GTPase.
Shi HY; Stafford LJ; Liu Z; Liu M; Zhang M
Cell Motil Cytoskeleton; 2007 May; 64(5):338-46. PubMed ID: 17301947
[TBL] [Abstract][Full Text] [Related]
17. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
Morgan MA; Sebil T; Aydilek E; Peest D; Ganser A; Reuter CW
Br J Haematol; 2005 Sep; 130(6):912-25. PubMed ID: 16156861
[TBL] [Abstract][Full Text] [Related]
18. The insert region of RhoA is essential for Rho kinase activation and cellular transformation.
Zong H; Kaibuchi K; Quilliam LA
Mol Cell Biol; 2001 Aug; 21(16):5287-98. PubMed ID: 11463812
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of transendothelial migration and invasion of human breast cancer cells by preventing geranylgeranylation of Rho.
Kusama T; Mukai M; Tatsuta M; Nakamura H; Inoue M
Int J Oncol; 2006 Jul; 29(1):217-23. PubMed ID: 16773203
[TBL] [Abstract][Full Text] [Related]
20. In vitro guanine nucleotide exchange activity of DHR-2/DOCKER/CZH2 domains.
Côté JF; Vuori K
Methods Enzymol; 2006; 406():41-57. PubMed ID: 16472648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
